Simon Xi, Rgenta Therapeutics CEO

Lund­beck-part­nered pre­clin­i­cal biotech nabs Se­ries A from As­traZeneca

Cam­bridge, MA biotech Rgen­ta Ther­a­peu­tics has se­cured $52 mil­lion in a Se­ries A to take oral small mol­e­cules in­to the clin­ic.

The 20-per­son biotech, which is al­ready al­lied with Lund­beck, looks to ink more phar­ma part­ner­ships with­in its core ar­eas of on­col­o­gy and neu­ro­science rare dis­eases, as well as in oth­er dis­ease ar­eas the start­up thinks the RNA-tar­get­ing plat­form can go, CSO Travis Wa­ger told End­points News ahead of the Tues­day morn­ing news.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.